Epilepsy - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 247 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Epilepsy - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Epilepsy - Pipeline Review, H2 2014', provides an overview of the Epilepsy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epilepsy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Epilepsy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Epilepsy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Epilepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Epilepsy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Epilepsy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Epilepsy Overview 9
Therapeutics Development 10
Pipeline Products for Epilepsy - Overview 10
Pipeline Products for Epilepsy - Comparative Analysis 11
Epilepsy - Therapeutics under Development by Companies 12
Epilepsy - Therapeutics under Investigation by Universities/Institutes 17
Epilepsy - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Epilepsy - Products under Development by Companies 22
Epilepsy - Products under Investigation by Universities/Institutes 26
Epilepsy - Companies Involved in Therapeutics Development 27
Allergan, Inc. 27
Neurocrine Biosciences, Inc. 28
Novartis AG 29
Acorda Therapeutics, Inc. 30
Astellas Pharma Inc. 31
Chong Kun Dang Pharmaceutical Corp. 32
Eisai Co., Ltd. 33
H. Lundbeck A/S 34
Pfizer Inc. 35
UCB S.A. 36
Aeolus Pharmaceuticals, Inc. 37
GW Pharmaceuticals plc 38
Anavex Life Sciences Corp. 39
Bionomics Limited 40
Paloma Pharmaceuticals, Inc. 41
D-Pharm Ltd. 42
VistaGen Therapeutics , Inc. 43
INSYS Therapeutics, Inc. 44
Upsher-Smith Laboratories, Inc. 45
Snowdon Inc. 46
Lipicard Technologies Limited 47
MedGenesis Therapeutix Inc. 48
Celentyx Ltd. 49
Adamas Pharmaceuticals, Inc. 50
Concert Pharmaceuticals, Inc. 51
Knopp Biosciences LLC 52
Biovista Inc. 53
Asklepios BioPharmaceutical, Inc. 54
Marinus Pharmaceuticals, Inc. 55
Bial - Portela & Ca, S.A. 56
Lohocla Research Corporation 57
Desitin Arzneimittel GmbH 58
Vichem Chemie Research Ltd. 59
MarcoPolo Pharmaceuticals SA 60
Aestus Therapeutics, Inc. 61
Convergence Pharmaceuticals Ltd. 62
BioCrea GmbH 63
Advicenne Pharma 64
SciFluor Life Sciences, LLC 65
Epirus Biopharmaceuticals, Inc. 66
Glialogix, Inc. 67
Epilepsy - Therapeutics Assessment 68
Assessment by Monotherapy Products 68
Assessment by Target 69
Assessment by Mechanism of Action 73
Assessment by Route of Administration 78
Assessment by Molecule Type 80
Drug Profiles 82
lacosamide - Drug Profile 82
perampanel - Drug Profile 86
carbamazepine - Drug Profile 88
levetiracetam - Drug Profile 90
ADV-5803 - Drug Profile 91
diazepam - Drug Profile 92
lacosamide - Drug Profile 94
brivaracetam - Drug Profile 98
diazepam - Drug Profile 100
eslicarbazepine acetate - Drug Profile 101
lacosamide - Drug Profile 104
everolimus - Drug Profile 108
naluzotan - Drug Profile 112
DP-VPA - Drug Profile 113
ganaxolone - Drug Profile 115
VLB-01 - Drug Profile 117
topiramate - Drug Profile 118
CX-1010 - Drug Profile 119
tonabersat - Drug Profile 120
GWP-42006 - Drug Profile 121
AV-101 - Drug Profile 122
INS-001 - Drug Profile 124
PF-04895162 - Drug Profile 125
ADV-6770 - Drug Profile 126
CKD-903 - Drug Profile 127
ANAVEX-2-73 - Drug Profile 128
Small Molecules for CNS Disorders - Drug Profile 129
ANAVEX-19-144 - Drug Profile 130
P-529 - Drug Profile 131
DP-VPA - Drug Profile 133
liatermin - Drug Profile 135
BVA-601 - Drug Profile 138
Small Molecules for Neurological Disorders - Drug Profile 139
AEOL-11207 - Drug Profile 140
C-10068 - Drug Profile 141
Z-944 - Drug Profile 142
Drug for Epilepsy - Drug Profile 143
VID-45110 - Drug Profile 144
BNP-TLE - Drug Profile 145
SL-327 - Drug Profile 146
Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Drug Profile 147
Drug to Activate GABA Receptor for Epilepsy - Drug Profile 148
KM-314 - Drug Profile 149
KM-113 - Drug Profile 150
SF-0034 - Drug Profile 151
2-DG - Drug Profile 152
ADV-6769 - Drug Profile 154
LT-4121 - Drug Profile 155
LT-4122 - Drug Profile 156
LT-4123 - Drug Profile 157
LT-4124 - Drug Profile 158
LT-4125 - Drug Profile 159
LT-4126 - Drug Profile 160
MRS-5474 - Drug Profile 161
GLX-1112 - Drug Profile 162
Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus - Drug Profile 163
Small Molecules to Inhibit Dynamin for Epilepsy and Oncology - Drug Profile 164
Small Molecules to Inhibit NMDA Receptor and GABAA Receptor for CNS - Drug Profile 165
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 166
MSP - Drug Profile 167
ESB - Drug Profile 168
EMSP - Drug Profile 169
ESBB - Drug Profile 170
SCT-66 - Drug Profile 171
VAD-1 - Drug Profile 172
VAD-2 - Drug Profile 173
VU-0456810 - Drug Profile 174
CNV-1061436 - Drug Profile 175
Cannabidiol - Drug Profile 176
FV-082 - Drug Profile 177
FV-137 - Drug Profile 178
Small Molecule to Inhibit Sodium Channel for Epilepsy - Drug Profile 179
Small Molecules for Epilepsy - Drug Profile 180
Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 182
VB-3323 - Drug Profile 183
Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 184
Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 185
Small Molecule for Central Nervous System - Drug Profile 186
AEOL-1114B - Drug Profile 188
AEOL-11203 - Drug Profile 189
AVL-5189 - Drug Profile 190
Cell Therapy for Neurological Disorders - Drug Profile 191
Small Molecules to Agonize GABA-A Receptor For Epilepsy - Drug Profile 192
Gene Therapy for Epilepsy - Drug Profile 193
UBP-608 - Drug Profile 194
Small Molecules to Block Kir Channel for Cardiovascular and CNS - Drug Profile 195
PRTT-200 - Drug Profile 196
IPR-003 - Drug Profile 197
Small Molecule to Target mGluR5 and mGluR6 for Neurological Disorders - Drug Profile 198
ADS-8800 Series - Drug Profile 199
Epilepsy - Recent Pipeline Updates 200
Epilepsy - Dormant Projects 227
Epilepsy - Discontinued Products 231
Epilepsy - Product Development Milestones 232
Featured News & Press Releases 232
Appendix 239
Methodology 239
Coverage 239
Secondary Research 239
Primary Research 239
Expert Panel Validation 239
Contact Us 240
Disclaimer 240

List of Tables
Number of Products under Development for Epilepsy, H2 2014 17
Number of Products under Development for Epilepsy - Comparative Analysis, H2 2014 18
Number of Products under Development by Companies, H2 2014 20
Number of Products under Development by Companies, H2 2014 (Contd..1) 21
Number of Products under Development by Companies, H2 2014 (Contd..2) 22
Number of Products under Development by Companies, H2 2014 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H2 2014 25
Comparative Analysis by Late Stage Development, H2 2014 26
Comparative Analysis by Clinical Stage Development, H2 2014 27
Comparative Analysis by Early Stage Development, H2 2014 28
Products under Development by Companies, H2 2014 29
Products under Development by Companies, H2 2014 (Contd..1) 30
Products under Development by Companies, H2 2014 (Contd..2) 31
Products under Development by Companies, H2 2014 (Contd..3) 32
Products under Investigation by Universities/Institutes, H2 2014 33
Epilepsy - Pipeline by Allergan, Inc., H2 2014 34
Epilepsy - Pipeline by Neurocrine Biosciences, Inc., H2 2014 35
Epilepsy - Pipeline by Novartis AG, H2 2014 36
Epilepsy - Pipeline by Acorda Therapeutics, Inc., H2 2014 37
Epilepsy - Pipeline by Astellas Pharma Inc., H2 2014 38
Epilepsy - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2014 39
Epilepsy - Pipeline by Eisai Co., Ltd., H2 2014 40
Epilepsy - Pipeline by H. Lundbeck A/S, H2 2014 41
Epilepsy - Pipeline by Pfizer Inc., H2 2014 42
Epilepsy - Pipeline by UCB S.A., H2 2014 43
Epilepsy - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2014 44
Epilepsy - Pipeline by GW Pharmaceuticals plc, H2 2014 45
Epilepsy - Pipeline by Anavex Life Sciences Corp., H2 2014 46
Epilepsy - Pipeline by Bionomics Limited, H2 2014 47
Epilepsy - Pipeline by Paloma Pharmaceuticals, Inc., H2 2014 48
Epilepsy - Pipeline by D-Pharm Ltd., H2 2014 49
Epilepsy - Pipeline by VistaGen Therapeutics , Inc., H2 2014 50
Epilepsy - Pipeline by INSYS Therapeutics, Inc., H2 2014 51
Epilepsy - Pipeline by Upsher-Smith Laboratories, Inc., H2 2014 52
Epilepsy - Pipeline by Snowdon Inc., H2 2014 53
Epilepsy - Pipeline by Lipicard Technologies Limited, H2 2014 54
Epilepsy - Pipeline by MedGenesis Therapeutix Inc., H2 2014 55
Epilepsy - Pipeline by Celentyx Ltd., H2 2014 56
Epilepsy - Pipeline by Adamas Pharmaceuticals, Inc., H2 2014 57
Epilepsy - Pipeline by Concert Pharmaceuticals, Inc., H2 2014 58
Epilepsy - Pipeline by Knopp Biosciences LLC, H2 2014 59
Epilepsy - Pipeline by Biovista Inc., H2 2014 60
Epilepsy - Pipeline by Asklepios BioPharmaceutical, Inc., H2 2014 61
Epilepsy - Pipeline by Marinus Pharmaceuticals, Inc., H2 2014 62
Epilepsy - Pipeline by Bial - Portela & Ca, S.A., H2 2014 63
Epilepsy - Pipeline by Lohocla Research Corporation, H2 2014 64
Epilepsy - Pipeline by Desitin Arzneimittel GmbH, H2 2014 65
Epilepsy - Pipeline by Vichem Chemie Research Ltd., H2 2014 66
Epilepsy - Pipeline by MarcoPolo Pharmaceuticals SA, H2 2014 67
Epilepsy - Pipeline by Aestus Therapeutics, Inc., H2 2014 68
Epilepsy - Pipeline by Convergence Pharmaceuticals Ltd., H2 2014 69
Epilepsy - Pipeline by BioCrea GmbH, H2 2014 70
Epilepsy - Pipeline by Advicenne Pharma, H2 2014 71
Epilepsy - Pipeline by SciFluor Life Sciences, LLC, H2 2014 72
Epilepsy - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 73
Epilepsy - Pipeline by Glialogix, Inc., H2 2014 74
Assessment by Monotherapy Products, H2 2014 75
Number of Products by Stage and Target, H2 2014 78
Number of Products by Stage and Mechanism of Action, H2 2014 82
Number of Products by Stage and Route of Administration, H2 2014 86
Number of Products by Stage and Molecule Type, H2 2014 88
Epilepsy Therapeutics - Recent Pipeline Updates, H2 2014 207
Epilepsy - Dormant Projects, H2 2014 234
Epilepsy - Dormant Projects (Contd..1), H2 2014 235
Epilepsy - Dormant Projects (Contd..2), H2 2014 236
Epilepsy - Dormant Projects (Contd..3), H2 2014 237
Epilepsy - Discontinued Products, H2 2014 238